Where does AnaptysBio, Inc.'s income statement data come from?

Every line is extracted from AnaptysBio, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

	TTM Q1 '26	TTM Q4 '25	TTM Q3 '25	TTM Q2 '25	TTM Q1 '25
Total revenue	$232.39M-0.9%	$234.6M+38.4%	$169.47M+37.6%	$123.16M+10.1%	$111.87M+22.6%
Research and development	$128.78M-5.3%	$135.97M-11.1%	$153M-6.6%	$163.81M-2.5%	$167.98M+2.5%
General and administrative	$62.81M+23.8%	$50.74M+12.4%	$45.14M-0.8%	$45.5M+3.0%	$44.18M+4.2%
Other operating expenses	$191.59M+2.6%	$186.71M-5.8%	$198.14M-5.3%	$209.3M-1.3%	$212.16M+2.9%
Total operating expenses	$191.59M+2.6%	$186.71M-5.8%	$198.14M-5.3%	$209.3M-1.3%	$212.16M+2.9%
Operating income	$40.8M-14.8%	$47.9M+267%	-$28.68M+66.7%	-$86.14M+14.1%	-$100.29M+12.8%
Operating margin	17.6%-2.9pp	20.4%+37.3pp	-16.9%+53.0pp	-69.9%+19.7pp	-89.6%+36.3pp
Interest income	$11.74M-13.0%	$13.5M-16.9%	$16.25M-12.9%	$18.65M-4.9%	$19.62M-0.9%
Other income (expense), net	-$67.43M-10.6%	-$60.96M-9.1%	-$55.88M-20.5%	-$46.38M-15.1%	-$40.29M-33.1%
Income before income taxes	——	——	-$84.55M+36.2%	-$132.52M+5.7%	-$140.58M+3.2%
Income tax expense	$160K-2.4%	$164K—	——	——	——
Net income	——	——	-$84.63M+36.2%	-$132.59M+5.7%	-$140.62M+3.2%
Diluted earnings per share	——	——	-$2.76+37.6%	-$4.42+7.7%	-$4.79+7.0%
Basic earnings per share	——	——	-$2.74+38.0%	-$4.42+7.7%	-$4.79+7.0%
Weighted-average shares, diluted	115.3M-1.7%	117.2M+0.3%	116.9M+0.1%	116.7M+1.3%	115.3M+3.4%
Weighted-average shares, basic	114.1M-1.7%	116M+0.3%	115.7M-0.9%	116.7M+1.3%	115.3M+3.4%
Noncash Advance Future Royalties Interest Expense	$82.69M+3.5%	$79.89M+3.0%	$77.59M+10.1%	$70.48M+14.0%	$61.83M+23.4%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent	——	——	-$85.34M+35.4%	-$132.19M+5.5%	-$139.84M+3.0%
Interest Income, Other	$11.74M-13.0%	$13.5M-16.9%	$16.25M-12.9%	$18.65M-4.9%	$19.62M-0.9%
Unrealized gains (losses) on available-for-sale securities	-$307K+6.7%	-$329K—	——	——	——
Other income, net (Note 6)	$3.53M-35.0%	$5.43M-0.4%	$5.45M+0.1%	$5.45M+184%	$1.92M+13,600%
Acquired in-process research and development expenses	——	$0—	$0—	$0—	$0—
Research and development expense	——	——	——	——	$164.06M+0.1%
Revenue From Contract With Customer Excluding Assessed Tax	$232.39M-0.9%	$234.6M+38.4%	$169.47M+37.6%	$123.16M+10.1%	$111.87M+22.6%
EBIT	$40.8M-14.8%	$47.9M+267%	-$28.68M+66.7%	-$86.14M+14.1%	-$100.29M+12.8%
EBITDA	$41.34M-14.7%	$48.46M+272%	-$28.1M+67.2%	-$85.56M+14.2%	-$99.7M+12.8%
EBITDA	$41.34M-14.7%	$48.46M+272%	-$28.1M+67.2%	-$85.56M+14.2%	-$99.7M+12.8%
EBITDA margin	17.8%-2.9pp	20.7%+37.2pp	-16.6%+52.9pp	-69.5%+19.7pp	-89.1%+36.1pp
EBIT	$40.8M-14.8%	$47.9M+267%	-$28.68M+66.7%	-$86.14M+14.1%	-$100.29M+12.8%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Where does AnaptysBio, Inc.'s income statement data come from?: Every line is extracted from AnaptysBio, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.